Endoplasmic reticulum (ER) oxidation I (ERO1
1
) is a conserved eukaryotic flavin adenine nucleotide (FAD)-containing enzyme that promotes disulfide bond formation by accepting electrons from reduced protein disulfide isomerase (PDI) and passing them on to molecular oxygen. While disulfide bond formation is an essential process, recent experiments suggest a surprisingly broad tolerance to genetic manipulations that attenuate the rate of disulfide bond formation and that a hyperoxidizing ER may place stressed cells at a disadvantage. In this study we report on the development of a highthroughput in vitro assay for mammalian ERO1a activity and its application to identify small molecule inhibitors. The inhibitor EN460 (IC 50 = 1.9 µM) interacts selectively with the reduced, active form of ERO1a and prevents its re-oxidation. Despite rapid and promiscuous reactivity with thiolates, EN460 exhibits selectivity for ERO1. This selectivity is explained by the rapid reversibility of EN460's reaction with unstructured thiols, in contrast to the formation of a stable bond with ERO1a 1 Non standard abbreviations: AUR, Amplex Ultra Red; DTNB, 1 mM 5,5′-dithiobis(2-nitrobenzoic acid; DTT, dithiothreitol; ERO1, Endoplasmic reticulum oxidation 1; FAD, flavin-adenine dinucleotide; PDI, protein disulfide isomerase; TCEP, tris(2-carboxyethyl)phosphine; THP, Tri(hydroxypropyl)phosphine followed by displacement of bound FAD from the enzyme's active site. Modest concentrations of EN460 and a functionally related inhibitor, QM295, promote signaling in the unfolded protein response and pre-condition cells against severe ER stress. Together, these observations point to the feasibility of targeting ERO1a's enzymatic activity with small molecule inhibitors. Disulfide bonds stabilize the tertiary structures of secreted proteins (1) , and disulfide formation is essential in all known life forms. The oxidative process that generates disulfide bonds in eukaryotes is accelerated by the formation of mixed disulfides between ER resident oxidoreductases, such as the protein disulfide isomerases (PDIs), and reduced cysteine residues on newly-translocated client proteins. Productive resolution of these mixed disulfides transfers the disulfide to the client protein and leaves the PDIs in a reduced state (2) . Reduced PDIs are enzymatically re-oxidized by an ER oxidase, ERO1, conserved from yeast to mammals (reviewed in: 3,4). Yeast ERO1 contains a flavin adenine dinucleotide (FAD) tightly bound to a four helical bundle motif also found in other sulfhydryl oxidases (5) . A series of disulfide exchange reactions --first between reduced PDI and a shuttle disulfide on ERO1 and then to an ERO1 disulfide lying adjacent to the isoalloxazine ring --leads to the reduction of the flavin and the eventual transfer of a pair of electrons to molecular oxygen (4) . This disulfide relay results in the generation of one ERO1a inhibition with small molecules page 2 molecule of H 2 O 2 for each disulfide bond formed in the ER (6) . In addition to the shuttle and active-site cysteines, ERO1 has several regulatory cysteines that form disulfide bonds that restrain the enzymatic activity of the fully oxidized enzyme (7, 8) . ERO1 genes are also under transcriptional control, and their mRNA levels increase with the load of unfolded reduced proteins in the ER -a phenomenon mediated by the unfolded protein response (9, 10) . ERO1 is an essential enzyme in yeast, and its dysfunction leads to a rapid decline in oxidative protein folding, strong activation of the unfolded protein response, and marked loss of viability (11, 12) . Interestingly, more modest attenuation of ERO1 activity improves the fitness of yeast challenged with high levels of protein misfolding in their ER (ER stress) (13) . A similar situation prevails in worms; the single ero-1 gene is essential, yet its partial inactivation enhances survival of worms exposed to the ER stressinducing glycosylation inhibitor tunicamycin (14) . Furthermore, compromise of ero-1 in the adult also extends the life span of worms that are not exposed to conditions that promote unusual levels ER stress (15) . These observations suggest potential benefits for partial inhibition of ERO1. Mammals have two ERO1 isoforms encoded by separate genes (10) . ERO1a is broadly expressed, whereas ERO1b is substantially restricted to the endocrine pancreas (16, 17) . Interestingly, mice homozygous for nearly complete loss-of-function mutations in both isoforms are viable and have a very mild kinetic defect in oxidative protein folding in explanted cells (17) . These observations point to the wide latitudes allowed for ERO1 activity in mammals and hold the prospect of targeting the enzyme with inhibitors. Here we report on the application of a high-throughput assay for ERO1a activity to the discovery of small molecule inhibitors, and on the biochemical and cellular characterization of an inhibitor with a surprising mechanism for attaining specificity.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification-A fusion protein of GST-SMT3-mouse ERO1a (residues 23-464) was expressed in the Rosetta (DE3) bacterial strain (Novagen). After growth at 37˚C to A 600 = 0.6 -0.8, the culture was shifted to 18˚C and isopropyl-β-D-thiogalactoside (IPTG) was added to 0.5 mM for an overnight incubation. Bacteria were harvested by centrifugation; resuspended in lysis buffer (20 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 10 mM imidazole) supplemented with protease inhibitors (200 µM phenylmethylsulfonyl fluoride [PMSF], 1 mg/ml pepstatin A) and lysed by high pressure cell disruption. To remove cell debris, the lysate was centrifuged for 30 min at 13,500 rpm and the supernatant subjected to glutathione affinity chromatography (5 ml GSTrap 4B, GE Healthcare). Bacterially expressed and purified Ulp1p protease (18) was added to the purified protein and incubated overnight at 4˚C to cleave the GST-SMT3 from the ERO1a (23-464) prior to further gel filtration on a Hi Load 16/60 Superdex-75 prep grade column. The cleaved ERO1a (23-464) protein was reapplied to glutathione beads, and the flow through was collected. The concentration of the purified protein was determined spectroscopically at 280 nm and 446 nm in 6 M guanidine HCl and 10 mM phosphate buffer (pH 6.8) assuming an extinction coefficient of 90,630 M -1 cm -1 (apo-ERO1a) and 11,300 M -1 cm -1 (FAD). All protein concentrations reported throughout this manuscript were determined similarly. Where indicated 500 µl aliquots of TrxA in Buffer A (65 mM NaCl, 20 mM sodium phosphate buffer, pH=7.4, 1 mM EDTA) were reduced with a 100-fold excess of dithiothreitol (DTT) for 30 min at room temperature and excess reductant removed by size exclusion using a PD-10 gel filtration (GE Healthcare) equilibrated with buffer A. Fractions of 500 µl were collected and the thiol titer for pooled reduced thioredoxin (TrxA red ) fractions was determined using aliquots diluted into 1 mM 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB, Sigma) and measuring the average absorbance at 412 nm. Amplex Ultra Red fluorescence-ERO1a (23-464), between 10 nM and 200 nM, and bacteriallyexpressed TrxA red were combined in a 20 µl reaction in Buffer A in a 384-well format black round bottom plate (Corning #3677) with 0.1 U/ml horseradish peroxidase (Worthington), 5 µM AUR (InVitrogen) at room temperature and read kinetically at 535 ± 20 nm excitation and 590 ± 20 nm emission on a TECAN F500 fluorescent plate reader. Inhibitors, EN460 (Benzoic acid, 2-chloro- (TimTec ST05611) and QM295  (5(4H)-Isoxazolone, 4-[(4-hydroxy-3-methoxyphenyl)methylene]-3-phenyl, (Chembridge 5904135) constituted to 10 mM in 100% DMSO, were added where indicated. Oxygen Consumption-Oxygen consumption was measured using an Oxygraph Clark-type oxygen electrode (Hansatech Instruments, Pentney, Kings Lynn, U.K.). All experiments were done at room temperature in air-saturated buffer at sea level (~250 µM O 2 in buffer A) as described (6) . Oxygen levels were monitored until a linear baseline was established, and catalytic oxygen consumption was initiated by the addition of TrxA red (50 µM) into a 1 ml reaction mixture containing 1 µM ERO1a (23-464) with or without the indicated compounds (50 µM) with a final DMSO concentration of 2%. Ellman's Assay-200 nM ERO1a, 20 µM TrxA red , 200 µM DTT with the indicated concentration of inhibitor were combined in a 384-well format white walled clear flat bottom plate (Falcon 3963) in a 20 µl total reaction volume. At endpoint, 0.5 mM DTNB was added and the absorbance at 405 nm was read on a TECAN F500 plate reader, essentially as described (19) . Mobility Shift Analysis of ERO1a oxidative statusERO1a (1 µM) was reacted with TrxA red (10 µM) for the indicated amount of time ± inhibitors (25 µM) before quenching with 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) (2 mM) and SDS (4%) for 1 h in the dark as described (7). To detect ERO1a, samples were resolved by non-reducing SDS-PAGE (10%) and immunoblotted with rabbit polyclonal serum raised to ERO1a (residues 23-464) protein. To detect TrxA, samples were resolved by nonreducing Tris-Tricine-PAGE (16.5%) and stained with Coomassie blue. Absorbance Spectroscopy-The absorbance spectra of compound EN460 and the indicated proteins, were measured in a diode array (Agilent HP 8453) using a quartz cuvette with a path-length of 1 cm. Absorbance of EN460 (100 µM) following reaction with DTT, reduced glutathione (GSH), THP, or TCEP (all 500 µM) was measured kinetically in 1 ml of buffer A (pH 6.5) and again following the addition of N-ethyl maleimide (NEM, 4 mM).
FAD fluorescence-ERO1a (150 µM), TrxA (50 µM), EN460 (250 µM), and DTT (2 mM) were combined in 100 µl of buffer A for 60 min at room temperature in the dark, followed by gel filtration (G50 Sephadex, GE Healthcare). Samples were divided into 3 aliquots of 35 µl and exposed to THP (2 mM), FAD (1 mM), or both, where indicated, for 2 h at room temperature in the dark followed by a second gel filtration. ERO1a activity was measured by AUR assay. Where indicated, FAD concentration was determined by first denaturing in 8M guanidine HCl, followed by measuring FAD fluorescence at 450 ex and 535 em at pH 2.
Effect of inhibitors on ERO1a redox status in vivo-
Mouse Embryonic Fibroblast (MEF) cells were cultured in DMEM supplemented with 10% FCS and plated the day before the experiment at 70% confluence in 6-well dishes. Cells were challenged with DTT (10 mM) and/or the indicated ERO1a inhibitors (50 µM) where indicated for 30 min. In the washout experiment, cells were washed free of the DTT and incubated with fresh media ± inhibitor. At harvest, PBS containing NEM (10 mM) was added and the cells subsequently kept on ice for 10 min in lysis buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, protease inhibitors, and 10 mM NEM). Protein concentrations were estimated by Lowry assay, and comparable amounts of protein were run on a non-reducing SDS-PAGE and immunoblotted with antiserum to ERO1a. Induction of an unfolded protein response-293T cells stably transfected with the ATF6-UPRELuciferase reporter (a gift of Michael Bassett and Jonathan Weissman, USCF) were treated overnight in low serum containing media (5%) with the indicated concentration of tunicamycin (Calbiochem) or inhibitors. Cells were lysed in 25 ml lysis buffer (25 mM glycylglycine, 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT, 1% Triton X-100), and luciferase was developed by addition of 25 ml of luciferase assay reagent (25 mM gly-gly, 15 mM MgSO 4 , 4 mM EGTA, 2 mM DTT, 11.7 mM potassium phosphate, 1.6 mM ATP, 0.2 mg/ml CoA, 500 µM Luciferin), and luminescence was read in a 96-well white plate (Costar #3912) on a TECAN F500 plate reader. Cell survival assay-The effect of ERO1a inhibitors on the survival of cells exposed to tunicamycin, were measured as described (20) . Briefly, Perk -/-mouse fibroblasts (21) were plated at a density of 5000 cells/well in 24-well plates. A day later, the media was replaced with complete medium with or without the compounds at 24 µM. The cells were incubated with or without compound for 7 h and then exposed to the indicated concentration of tunicamycin for another 24 h, in the continued presence of compound. The cells were then washed with PBS and returned to complete media. After an additional 12 days of culture, the media was replaced with fresh media containing 0.05 mg/ml WST-1 (Dojindo) and 0.05 mg/ml phenazine methosulfate (Sigma), and the OD 450 minus the OD 650 of 100 µl of medium from each well was measured after a 2-4 h incubation period.
RESULTS
A homogenous high-throughput assay for mammalian ERO1a activity. ERO1a catalyzes the transfer of a pair of electrons from reduced substrates to molecular oxygen with the formation of H 2 O 2 . A homogenous assay of ERO1a activity was developed in which reduced bacterial thioredoxin (TrxA red , a good in vitro surrogate for ERO1a's natural substrates) is reacted with purified recombinant mouse ERO1a in the presence of oxygen. The H 2 O 2 produced by this reaction drives the horseradish peroxidase (HRP)-mediated oxidation of Amplex Ultra Red (AUR) generating a fluorescent signal (Fig. 1A) .
When reactions were performed in the presence of a large excess of HRP, the rate of development of the fluorescent signal was limited by the concentration of TrxA red and by the amount of enzyme in the reaction. Under these conditions the Km for TrxA red was 3.1 µM (Fig. 1B) . At 20 µM TrxA red the enzyme showed a turnover number of 5 disulfide bonds generated per minute with initial rates that were linearly dependent on ERO1a concentration ( Fig. 1C and 1D ).
This assay was applied to a screen for small molecules that inhibit the development of the fluorescent signal. The assay performed well with Z values between 0.75 and 0.9 (Supplemental Fig 1) . Among 210,965 compounds in the primary screen (Supplemental Table 1 ), we identified 629 compounds that lowered AUR fluorescence by more than two-fold. Inhibitors were counterscreened for their activity against HRP in an assay that employed H 2 O 2 , HRP and AUR. Compounds that passed this test were re-screened for their ability to inhibit ERO1a in an orthogonal, colorimetric end point assay that detects the depletion of free thiols by ERO1a in the presence of TrxA red and dithiothreitol (DTT) by the loss of reactivity to the Ellman reagent, DTNB, (19) . Because the latter assay is performed at high concentrations of DTT (200 µM), it also selects against non-specific thiol-reactive compounds. Identification of ERO1a inhibitors. Compounds were stratified according to potency at the secondary screen level, and re-stocked from powder. Employing these selective criteria (Supplemental Fig. 2 ) left us with two candidate inhibitors: benzoic acid, 2-chloro-
, which we named EN460 in light of its enone group and molecular weight of 460 Da, and 5(4H)-isoxazolone, 4-[(4-hydroxy-3-methoxyphenyl)methylene]-3-phenyl, which we named QM295, in view of its quinone methide group and molecular weight of 295 Da, ( Fig. 2A) . Both compounds inhibited the development of AUR fluorescence in a kinetic assay (Fig. 2B) . The compound concentration needed to inhibit 50% of AUR fluorescence was nearly identical for both compounds, 1.9 µM (Fig. 2C ).
Both compounds also inhibited oxygen consumption by purified ERO1a in a reaction fed by TrxA red (Fig. 2D ). As neither assay could distinguish between inhibitors that bound TrxA red and those that targeted ERO1a, we challenged purified ERO1a with TrxA red in the presence or absence of compounds and monitored the ERO1a redox-state by labeling the free thiols with 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS). Like yeast ERO1, the cysteines in the mammalian enzyme were mostly oxidized in the basal state, and the protein demonstrated a high mobility in SDS-PAGE. Exposure to TrxA red lead to reduction of the regulatory disulfides, and a new steady-state was attained whereby the enzyme was reduced, activated, and AMS reactive, as demonstrated by its lower mobility on SDS-PAGE (Fig. 2E, compare lanes 9 & 10) . In the absence of inhibitor in the assay, ERO1a returned to its oxidized, AMS non-reactive, high mobility state following oxidation of the TrxA red , as reported in case of the yeast enzyme (7).
Though the inhibitors did not affect the reduction of ERO1a by TrxA red , they appeared to block ERO1a's ability to completely oxidize TrxA red in the assay (shown for EN460 in Fig. 2F , compare lanes 2 & 3 to lanes 4 & 5) and to return ERO1a to its high mobility state (Fig. 2E, compare  lanes 4, 8 & 12) . This inability to return to the high mobility state likely indicates a defect in ERO1a re-oxidation rather than a covalent modification by the compound that affects mobility, as ERO1a's position on the SDS-PAGE was unaffected by the compound alone (i.e., when AMS was omitted from the reaction, data not shown). Together, these experiments suggest that the inhibitors function not by interfering with the transfer of electrons from TrxA red to ERO1a, but rather by targeting the reduced enzyme such that further oxidation of dithiol substrates by molecular oxygen is compromised.
A similar phenomenon was observed in vivo. At steady state the ERO1a in mouse embryonic fibroblasts was mostly oxidized with high mobility on SDS-PAGE. Exposure of the cells to DTT (10 mM), lead to reduction of the disulfides in ERO1a and imparted a lower mobility on the protein in SDS-PAGE. Exposure of cells to EN460 or QM295 resulted in the accumulation of an ERO1a form with lower mobility, indicative of the reduced state (Fig. 3A) . At steady state, QM295 had a less prominent effect of ERO1a oxidation than EN460 (compare lanes 3 & 4 in Fig. 3A) . To confirm QM295's inhibitory effect we monitored ERO1a reoxidation following its reduction with DTT in cells and washout of the reductant. The presence of QM295 led to a marked delay in ERO1a reoxidation following DTT washout (Fig. 3B) . Together, these observations suggest that both compounds were able to inhibit the enzyme in vivo as well as in vitro.
Blocking ERO1 activity in yeast and worms activates the unfolded protein response (11, 12) . EN460 and QM295 were also found to activate an unfolded protein response (UPR) reporter in cultured 293T cells (Fig. 3C ). EN460 was a more potent activator, but its action was limited by toxicity at the highest concentrations used (not shown), whereas QM295 had a more shallow and sustained dose response.
Lowered levels of ERO1 activity can protect against severe ER stress in worms, yeast and cultured mammalian cells (13, 14, 17) . Consistent with these observations, we found that continuous exposure to low concentrations of EN460 (and to a lesser degree QM295) protected hypersensitive Perk -/-mouse embryonic fibroblasts (22) from subsequent exposure to tunicamycin (Fig. 3D) . Protection by ERO1a inhibitors was relatively modest, compared with a known protectant like TGD31BZ (20) , and was likely limited by toxicity. Nonetheless these observations point to the potential for ERO1a inhibitors to protect against the consequences of severe ER stress in mammalian cells.
Mechanism of action of EN460.
Hereafter we describe studies on the mechanism of action of the more potent inhibitor EN460.
A lag phase in EN460 inhibition of H 2 O 2 production in the fluorescent assay (data not shown), suggested the hypothesis that the enone functionality of the inhibitor ( Fig. 2A) reacts with cysteine residues uncovered during the reductive activation of ERO1a. To test for the irreversible inhibition predicted by this mechanism of action, we first exposed ERO1a (20 µM) to compound (250 µM) in the presence or absence of reduced substrate. We then diluted the mixture of enzyme and inhibitor 100-fold (to 200 nM and 2.5 µM, respectively) and compared the enzymatic activity in an assay that is sensitive to thiol depletion by ERO1a (Fig. 4A) . When added to this assay at 2.5 µM, EN460 had a very modest inhibitory effect (Fig. 4B, compare lane 8 & 9) . In contrast, when diluted to 2.5 µM final concentration after having been allowed to first react with the enzyme at 100-fold higher concentration, the inhibition was far more conspicuous (Fig. 4B, compare lane 8 & 12) . Furthermore, the degree of inhibition that persisted after dilution was greater in the sample in which ERO1a was first activated by reducing substrate when exposed to EN460 than in the sample in which ERO1a was oxidized and inactive when exposed to EN460 (Fig. 4B, compare lanes 10 &  12) .
In a related, confirmatory experiment, ERO1 and EN460 were allowed to react in the presence or absence of a reduced substrate, and the enzyme was then separated from the small molecules in the reaction mix by gel filtration and assayed kinetically using the AUR fluorescent assay (Fig. 4C ). ERO1a exposed to EN460 in the absence of reduced substrate retained most of its enzymatic activity following the removal of excess EN460 by gel filtration, whereas the sample that was exposed to inhibitor in the presence of reduced substrate showed very low activity following gel filtration (Fig. 4D) . Together, these experiments suggest that EN460 is an activitydependent, poorly reversible or irreversible inhibitor of ERO1.
EN460 is colored red and has a broad absorbance peak between 450-550 nm both in aqueous solutions and in DMSO. This chromophore is rapidly bleached by reductants such as the thiols in DTT, GSH, and the phosphine based reagents tris(hydroxypropyl)phosphine (THP) and tris[2-carboxyethyl] phosphine (TCEP). A rapid decrease in visible absorbance is accompanied by a corresponding increase at 290 nm ( Fig. 5A and 5B). Consistent with the enone reactive functionality of EN460, DTT (Fig. 5C ) and GSH (supplemental Fig. 3 ) form adducts with these thiols. These adducts are reversible as addition of excess NEM restored the absorbance peak at 470 nm and led to loss of chromophore at 290 nm. In contrast, the phosphines generate reduced forms of EN460 that are reversed only slightly by NEM (Fig. 5C -upper panel) .
Like its yeast counterpart, mammalian ERO1a exhibits a bright yellow color due to the presence of FAD bound tightly, but noncovalently, within the active site of the oxidase (blue trace, Fig. 6A ). The protein envelope contributes an additional absorbance band centered at 280 nm. In the experiments to follow, the subsequent modulation of the absorbance of ERO1a by covalent binding of EN460 was revealed after removing the spectral contribution of excess free reagent by gel filtration. When ERO1a was incubated with EN460 in the presence of TrxA red and DTT, the protein emerging from the gel filtration column showed notable additional absorbance at 290 nm and longer wavelengths (red trace, Fig. 6A ). This feature was dominated by the covalent modification of the ERO1a protein because incubation of EN460 with reduced TrxA red and DTT in the absence of the oxidase did not generate this absorbance (compare the grey and red traces in Fig. 6A ). Adduct formation between EN460 and reduced ERO1a was accompanied by considerable loss of the flavin absorbance envelope. In contrast, flavin was retained when reduced ERO1a was gel filtered without prior exposure to the inhibitor (purple trace, Fig. 6A) .
Before addressing the fate of the flavin prosthetic group upon reductive inactivation of ERO1a, we first examined the nature of the adduct between the pre-reduced oxidase and EN460. When inactivated ERO1a was denatured with guanidine HCl in the presence of the alkylating agent NEM, a rapid release of the original EN460 chromophore was seen (signaled by the increase in absorbance at 470 nm, and a corresponding disappearance of the 290 absorbance; Fig. 6C  bottom and top respectively) . Overall, the loss of the 470 nm absorbance of EN460 upon reaction with reduced ERO1a, the appearance of a new band at 290 nm, and the reversal of this absorbance pattern in the presence of NEM, are all consistent with the formation of a reversible thiol adduct (supplemental Fig. 3A) . However, unlike the model thiols discussed earlier, release of EN460 from ERO1a adducts was only efficiently accomplished following denaturation of the oxidase (red trace, Fig. 6C ).
To determine if the loss of flavin absorbance observed in the gel-filtered samples in Fig. 6A involved a direct modification of the flavin chromophore by EN460 or indirect disruption of the FAD binding site, again unmodified and modified ERO1a were separated from excess small molecules by gel filtration (Fig.  7A ) and attenuation of the FAD peak was confirmed (Fig. 7B) . Next, the purified ERO1a was exposed to NEM in the presence of guanidine HCl, which lead to release of the bound EN460 and appearance of a conspicuous absorbance peak at 470 nm, as expected (red trace, Fig. 7C ). The subsequent addition of THP to this solution bleached the enone absorbance but revealed very low residual flavin absorbance (yellow trace, Fig.  7C ). Control experiments showed that in the absence of EN460, neither exposure to THP nor guanidine HCl destroyed the FAD chromophore of ERO1a (blue and green traces, Fig. 7C ). Together, these observations suggest that exposure to EN460 leads to loss of the FAD from the holoenzyme.
Data presented in Fig. 7D provide further evidence that reductive inactivation of ERO1a by EN460 leads to weakened binding of FAD. As a control, untreated ERO1a was subject to gel filtration, and eluted fractions were analyzed for their FAD content by diluting them into guanidine HCl at pH 2 and measuring the fluorescence of the free FAD (which is conspicuous at low pH). ERO1a eluted in fraction F1 and the FAD fluorescence observed in the untreated sample reflected the expected release of the flavin from the denatured ERO1a. Subsequent fractions (F2-F10) exhibited very low residual flavin fluorescence, consistent with tight binding of FAD to apo-ERO1a. In contrast, F1 from EN460-inactivated ERO1a showed a residual flavin content of only ~ 20% of the control, and the bulk of the FAD fluorescence was distributed in the low molecular weight fractions (F2-F10) that emerge after the protein peak (Fig. 7D) . Thus, ERO1a eluting after reductive inactivation with EN460 is substantially lacking in FAD and is derivatized by attachment of EN460 to a protein thiol.
The recovery of EN460 absorbance at 470 nm following denaturation and alkylation of ERO1, provides a basis for estimating the stoichiometry of ERO1 and EN460's interaction: The concentration of ERO1 estimated from the protein absorbance and independently from the bound FAD absorbance of the starting material was 70 µM and 78 µM, respectively. After adjusting for the losses and dilution of the gel filtration procedure the estimated concentration of ERO1 in the experiment shown in Fig. 7 is 46 µM. The extinction coefficient of EN460 at 470 nm was measured as 32 mM -1 cm -1 , and the concentration of the EN460 therefore was ~20 µM. Given that about 1/3 of the FAD absorption remained associated with ERO1, the concentration of the inhibited enzyme is in the order of 30 µM, suggesting a 1:1 complex with EN460
Given the reversibility of EN460-thiol interactions we wanted to know if any of the inhibition of ERO1a by EN460 could be reversed by disruption of the enone-protein adduct and allowing FAD to rebind to the apoprotein. We exposed the gel filtered, EN460-inhibited ERO1a to THP alone, FAD alone, and THP + FAD for 2 hours at room temperature, purified the protein away from small molecules by a second round of gel filtration, and assayed its enzymatic activity by AUR fluorescence (Fig. 8A) . Interestingly, FAD alone had little affect, THP alone led to some recovery, but the combination of THP and FAD led to significant recovery in enzymatic activity (Fig. 8B) . Next we denatured the protein in each sample and measured the amount of released FAD fluorescence; it was conspicuous only in the sample that had been exposed to THP and FAD prior to the terminal gel filtration (Fig. 8C ). These observations suggested that EN460 labeling of ERO1a promoted loss of FAD, but removal of the enone, by irreversible derivatization with THP, allowed FAD rebinding and the recovery of some oxidase activity.
DISCUSSION
Here we describe the application of a high throughput assay of ERO1a enzymatic activity to the identification of small molecule enzyme inhibitors and report on the characterization of two such inhibitors. Predictably, the inhibitors promoted an unfolded protein response and provided protection against otherwise lethal levels of ER stress in susceptible cultured cells. These findings point to the feasibility of targeting ERO1a with small molecules and to the potential utility of this strategy for protecting ER-stressed cells.
The most interesting and important lesson of our study concerns the mechanism of action of EN460. Multiple lines of evidence suggest that at least one cysteine residue, generated during activation and/or catalytic turnover of ERO1a, is a target of EN460. This reaction leads to inactivation of the enzyme. Clearly, the enone function of EN460 is a potent Michael acceptor for a range of thiols including DTT and glutathione. The enone functionality is required for inhibition, as irreversible reduction by phosphines inactivates EN460. Thiol adduct formation is signaled by loss of the characteristic red color of EN460 and is accompanied by the appearance of a strong new UV absorbance at 290 nm. This UV feature is also observed in ERO1a labeled with EN460 after reductive activation of the enzyme.
Thiol-mediated EN460 adducts can be reversed rapidly upon addition of the thiol-specific maleimide NEM. We have documented this reaction with EN460 adducts of DTT and GSH, and found that it is also observed with the comparable ERO1a adduct, providing that the protein is first denatured. The reversibility of this enone-thiol adduct suggests that the interaction of EN460 and ERO1a is stabilized by other, presumably non-covalent interactions between the protein and the compound. It is likely that the instability of the ERO1a-EN460 adduct that follows denaturation has frustrated our effort to map adduct-containing peptides on ERO1a. While it is formally possible that the conformational changes underlying the allosteric activation of ERO1a by reduction of regulatory disulfide bonds exposes a non-thiol-nucleophile that reacts with the EN460, this mechanism is disfavored by the potency of the thiol-selective enone, NEM, in competing with EN460. Finally phosphine reductants are largely irreversible reductants of EN460, and their reactivity consumes any enone released from these Michael adducts. Overall, EN460 forms adducts with activated ERO1a that can be reversed by reagents that either compete with protein thiols or that consume the inhibitor itself.
Despite its non-selective reactivity with free thiols, EN460 exhibits surprising specificity towards ERO1a. Thus, in vitro, micromolar concentrations of EN460 can inhibit ERO1a even in the presence of a vast molar excess of competing thiols. In vivo, non-selective reactivity with free thiols may explain the leftward shift in the dose response curve (compared with the in vitro situation). Nonetheless EN460 is able to inhibit its target in vivo, apparently in the presence of millimolar concentrations of competing thiols in the cell.
Adduct formation to ERO1a also leads to a significant weakening of the binding of the FAD prosthetic group. Weakening of FAD-binding is not observed when reduced and activated ERO1a is exposed to high concentrations of the nonselective thiol-reactive inhibitor NEM (data not shown), suggesting the possibility that elements of the ring structure of EN460 may serve to displace flavin from ERO1a, contributing to loss of enzyme activity and helping to explain the avidity with which EN460 captures ERO1a.
Despite the presence of several potentially reactive thiols in ERO1 (7), the stoichiometry of the enzyme inhibitor complex is close to 1:1. This finding is consistent with the idea that the adduct is stabilized by a limited set of conformations and may possibly be restricted to a limited subset of ERO1's free thiols.
The mechanism for EN460, outlined here, may be shared by other inhibitors whose structures suggest the ability to react with free thiols. For example, the quinone methide functionality of QM295 is a powerful Michael acceptor (23) . Similarly, the newly described Erodoxin (24) is predicted to form thiol adducts by substitution nucleophilic aromatic reaction S N Ar chemistry (Supplemental Fig 4) . Interestingly, Erodoxin, which is a potent inhibitor of yeast ERO1, has weak activity against mouse ERO1a (IC50>400 µM, data not shown) Assuming that the reactive thiol groups are conserved in the yeast and mammalian enzyme, this observation points to the importance of non-covalent interactions in enzyme inhibition. The mechanism proposed for EN460 selectivity also differs from that of other thiolreactive selective enzyme inhibitors. For example, the 6-or 7-acrylamido-4-anilinoquinazolines, PD160678 and PD168393, irreversibly inhibit the tyrosine kinase activity of the epidermal growth factor receptor by stably interacting with cysteine 773. However these compounds appear to have little promiscuous reactivity with other thiols (25) .
Neither EN460 nor QM295 are sufficiently selective to be of value as physiological probes into ER redox poise. Their relative low potency in vivo and their toxicity profile suggest the costs of promiscuous interactions with free thiols. Nonetheless, our study suggests that compounds with stronger noncovalent interactions and the ability to form otherwise reversible bonds with free thiols could emerge as potent inhibitors of enzymes like ERO1. Immunoblot of endogenous ERO1a in lysates prepared as in (A). The MEFs were exposed to a 30 min "pulse" of DTT (10 mM) followed by DTT free "chase" for the indicated time in the absence or presence of QM295 (50 µM). Shown is an experiment reproduced twice. C. Relative luciferase activity from an unfolded protein response reporter (ATF6::luciferase) in 293T cell line after 16 h exposure to the indicated concentrations of EN460 or QM295 or tunicamycin as a positive control. Values shown are the mean ± SD (n = 3) (p<0.05*, p<0.01**, two tailed unpaired students t-test compared to the untreated sample). D. Survival of ER stress-hypersensitive Perk -/-MEFs that received no treatment ("no tmt") or were treated with the indicated concentrations of EN460 or QM295 or TGD37BZ (a known protective compound, 20), followed by subsequent challenge with the indicated concentration of tunicamycin (Tm) for 24 h. Survival is expressed as relative amount of WST-1 reduced by Tm-exposed cells compared to unexposed cells (arbitrarily set to 100%). Values shown are the mean ± SD (n = 3) (p<0.05*, p<0.01**, two tailed unpaired students t-test, relative to no treatment cells at each concentration of tunicamycin). Spectroscopic evidence that the EN460 interaction with ERO1a thiols is stabilized by the protein structure. A. Comparison of the spectrum of protein samples after gel filtration: ERO1a alone, with TrxA and DTT, and after additionally including EN460 in the reductive incubation. A further control sample contained TrxA, DTT and EN460 but no ERO1a. B. Schema of the experimental design to test the reversibility of the EN460 interaction with ERO1a thiols by absorbance spectra. The color-coding of the experimental arms is maintained in panel C, below. C. Time-dependent change in absorbance of ERO1a that had been reacted with EN460 under reducing conditions and then gel filtered to remove un-bound small molecules, followed by denaturation in guanidine HCl (GDN), alkylation with N-ethyl maleimide (NEM) or a combination of both (all at t=0). Shown is a representative experiment reproduced three times. Absorbance (in the visible region of the spectra) of ERO1a, first reacted with EN460 (in the presence of TrxA, and DTT), and then gel filtered (to remove un-bound small molecules). Note the substantial disappearance of the FAD absorption spectrum in the sample that had been exposed to EN460. C. Visible absorbance of denatured and alkylated ERO1a that had or had not been previously reacted with EN460. Where indicated, THP was added to reduce the released EN460 and reveal any underlying FAD absorbance. D. FAD fluorescence of fractions from the gel-filtration of ERO1a that had or had not been reacted with EN460 under reducing conditions. The fractions were denatured and adjusted to pH 2, before measuring FAD fluorescence. Shown is a representative experiment reproduced three times. Time-dependent change of AUR fluorescence in an assay performed in the presence of uninhibited ERO1a, and EN460-inhibited ERO1a that had been subsequently incubated with THP, FAD or both, followed by gel filtration to remove unbound small molecules. C. FAD fluorescence of the protein peak (fraction 1) of gel-filtered ERO1a from the three experimental arms (as in fig. 7D ). 
